These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9514463)

  • 41. [Clinical trials on protective efficacy of statins for cardiovascular events due to hyperlipidemia (J-LIT, 4S, CARE, LIPID etc)].
    Higashikata T
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():628-36. PubMed ID: 15171447
    [No Abstract]   [Full Text] [Related]  

  • 42. Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty.
    Johansson SR; Wiklund O; Karlsson T; Hjalmarson A; Emanuelsson H
    Eur Heart J; 1991 Sep; 12(9):1020-8. PubMed ID: 1936002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: a new class of cholesterol-lowering agents.
    Gordon DJ; Rifkind BM
    Ann Intern Med; 1987 Nov; 107(5):759-61. PubMed ID: 3662286
    [No Abstract]   [Full Text] [Related]  

  • 44. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    Schiel R; Bambauer R; Müller UA
    Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent developments in coronary heart disease prevention: the Scandinavian and west of Scotland studies.
    Elam MB; Cushman W; Applegate WB; Heimberg M
    Tenn Med; 1997 May; 90(5):189-92. PubMed ID: 9130876
    [No Abstract]   [Full Text] [Related]  

  • 47. [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
    Einecke D
    MMW Fortschr Med; 2011 Dec; 153(49-50):17-8. PubMed ID: 22308584
    [No Abstract]   [Full Text] [Related]  

  • 48. [Lowering of the plasma lipid concentration with lovastatin. A clinical study in patients with primary hypercholesterolemia].
    Grüneberger S; Dreyer M; Kangah R; Reinicke A; Staisch C; Steinhagen-Thiessen E; Müller P; Simon B; Dammann HG
    Dtsch Med Wochenschr; 1989 Nov; 114(45):1734-9. PubMed ID: 2806106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
    Pedersen TR; Tobert JA
    Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Optimal lipid lowering therapy for coronary heart diseases patients in secondary prevention: moderate or aggressive LDL decrease preferred?].
    MMW Fortschr Med; 2006 Nov; 148(48):54-5. PubMed ID: 17615773
    [No Abstract]   [Full Text] [Related]  

  • 51. Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients.
    Lal SM; Katyal A
    Mo Med; 2002; 99(10):580-4. PubMed ID: 12534147
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
    Frisinghelli A; Mafrici A
    Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
    Hunninghake D; Bakker-Arkema RG; Wigand JP; Drehobl M; Schrott H; Early JL; Abdallah P; McBride S; Black DM
    J Fam Pract; 1998 Nov; 47(5):349-56. PubMed ID: 9834769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Use of statins in primary prevention: from the theoretical presuppositions to complex scenarios of the real world].
    Poli A; Menotti A
    G Ital Cardiol; 1999 Oct; 29(10):1123-30. PubMed ID: 10546121
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.
    McKenney JM; Barnett MD; Wright JT; Proctor JP
    Arch Intern Med; 1992 Sep; 152(9):1781-7. PubMed ID: 1520045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary prevention of coronary heart disease: implications of the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS).
    Brown AS
    Curr Cardiol Rep; 2000 Sep; 2(5):439-44. PubMed ID: 10980912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Primary and secondary prevention of coronary disease by statins].
    Ferrières J
    Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statins and the acute-phase response.
    Munford RS
    N Engl J Med; 2001 Jun; 344(26):2016-8. PubMed ID: 11430332
    [No Abstract]   [Full Text] [Related]  

  • 59. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Can aggressive efforts directed at lipid lowering post-PTCA reduce the risk of restenosis?
    Drown DJ
    Prog Cardiovasc Nurs; 1995; 10(2):40. PubMed ID: 7651950
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.